Requires the fee schedule for appropriate current procedural terminology and proprietary laboratory analysis codes be regularly updated for all mandatory biomarker precision medical testing coverage
This bill amends the social services law to require the Department of Health to regularly update the Medicaid fee schedule for mandatory biomarker precision medical testing coverage. The measure specifically directs the department to keep pricing current for appropriate Current Procedural Terminology (CPT) codes and Proprietary Laboratory Analysis (PLA) codes, which are used to bill for laboratory and diagnostic services.
The bill also requires the department, within 60 days of the act’s effective date, to update the fee schedule for services covered under the relevant Medicaid provision and to establish pricing for any covered testing not already included in the schedule. In practical terms, the bill is aimed at ensuring that biomarker testing services are reimbursed under an up-to-date payment structure rather than relying on outdated code listings or prices.
The bill would modify section 365-a of the social services law, which governs certain Medicaid-covered services, by adding a new requirement that the Department of Health regularly revise reimbursement rates and code references for biomarker precision testing. It would affect Medicaid administration, laboratory providers, and patients who rely on biomarker testing by making coverage pricing more responsive to new or changing diagnostic codes and tests.
Based on the available context, the bill appears to have a generally supportive policy rationale centered on keeping Medicaid reimbursement aligned with modern diagnostic testing. There is no recorded vote or committee transcript showing opposition or debate, and the bill was introduced and referred to the Assembly Health Committee, suggesting it was still in the early stages of consideration. The overall tone of the measure is technical and administrative rather than partisan.
The main potential point of contention is whether the Department of Health should be required to update fee schedules on a regular basis and within a short 60-day deadline, which could raise administrative and budgetary concerns. Another possible issue is the adequacy of reimbursement levels for biomarker precision testing: providers may favor higher or more flexible pricing, while state budget officials may be concerned about cost growth. No specific objections are documented in the provided materials, but these are the likely areas of debate.